MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that additional analyses of MediciNova’s completed clinical trial of MN-166 (ibudilast) in ALS (amyotrophic lateral sclerosis), which was conducted at Carolinas HealthCare System’s Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute, will be presented on December 5, 2019 at 10:30 am local time at the 30th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) in Perth, Australia.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of idiopathic pulmonary fibrosis (IPF). Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035. The allowed claims cover the use of MN-001 for treating a patient diagnosed with idiopathic pulmonary fibrosis.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of advanced nonalcoholic steatohepatitis (NASH). Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035. The allowed claims also cover advanced NASH patients that exhibit hepatic fibrosis, spider angiomata, ascites, splenomegaly, hard liver border, palmar erythema, asterixis, portal hypertension, hepatic scarring, cirrhosis, or hepatocellular carcinoma (HCC).

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Multiple Reasons for MediciNova to Move Higher MediciNova, Inc. (NASDAQ:MNOV) is a biopharmaceutical company focused on developing small molecule therapies for treating a range of diseases with unmet medical need. During this unprecedented time of the global coronavirus pandemic, where many activities unrelated to

If you own shares in MediciNova, Inc. (NASDAQ:MNOV) then it's worth thinking about how it contributes to the...

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT HERE Business Update Phase 3 Trial of MN-166 in ALS Underway In April 2019, MediciNova, Inc. (NASDAQ:MNOV) announced that following review of the protocol the U.S. Food and Drug Administration (FDA) determined that the company may proceed with the Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate development of MN-166 (ibudilast) for severe pneumonia and acute respiratory distress syndrome (ARDS). MediciNova’s decision to pursue development of this indication was based on positive results of a recent preclinical study in an animal model of ARDS (Med Sci Monit, 2020; 26: e922281).

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Masimo Corporation (NASDAQ: MASI) * Seattle Genetics, Inc. (NASDAQ: SGEN) * Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 7) * Celcuity Inc (NASDAQ: CELC) * Curis, Inc. (NASDAQ: CRIS) * Helius Medical Technologies Inc (NASDAQ: HSDT) * Menlo Therapeutics Inc (NASDAQ: MNLO) * TherapeuticsMD Inc (NASDAQ: TXMD) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)Stocks In Focus COVID-19 Test Sales to Lift GenMark's Q1 Results; Company Raises 2020 Guidance GenMark Diagnostics, Inc (NASDAQ: GNMK) announced preliminary first-quarter results, expecting revenues of about $38.7 million, a 80% year-over-year increase. The company noted that about 80% gross placements included interest in COVID-19 testing SARS-CoV-2 consumable revenues. Analysts, on average, estimate revenues of $24.8 million.The company also raised its full-year revenue guidance from $100-$110 million to $112-$122 million, while the consensus calls for revenues of $108.58 million.The stock climbed 29.56% to $5.83 in after-hours trading.Zomedica Prices Offering of Common Stock, Warrants Zomedica Pharmaceuticals Corp (NYSE: ZOM) said it has priced its previously announced public offering of 33.33 million shares and warrants to purchase up to 1.667 million shares. The company expects gross proceeds of about $4 million from the offering. The offering is expected to close on or about April 9.In after-hours trading, the shares shed 9.95% to 15 cents.Mersana Raises $65M Through At-The-Market Facility Mersana Therapeutics Inc (NASDAQ: MRSN) said it has raised gross proceeds of about $65 million through at-the-market facility with participation based on interest received from Avoro Capital Advisors LLC, Bain Capital Life Sciences, Consonance Capital Investors and David Mott, Mersana's Chairman.The company said it sold about 8.9 million shares at $5.50 per share and 2 million shares at the closing price of $7.74 per share, in each case the market price at the time of sale.Bristol-Myers Squibb Announces Acceptance of U.S. and European Regulatory Submissions for Combo Immunotherapy For Lung Cancer Bristol-Myers Squibb Co (NYSE: BMY) said the U.S. FDA accepted its sBLA for Opdivo-Yervoy combo with a limited course of chemotherapy for the first-line treatment of patients metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations. The European Medicines Agency has also validated a type II variation application for the same combo for the same indication, it added.Acceleron's Hypertension Drug Gets Breakthrough Therapy Designation Acceleron Pharma Inc (NASDAQ: XLRN) said the FDA has granted Breakthrough Therapy Designation to sotatercept for the treatment of patients with pulmonary arterial hypertension.FDA Extends Review Period For Roche's Spinal Muscular Atrophy Drug By 3 Months Roche Holdings AG Basel (OTC: RHHBY) said the FDA has extended the PDUFA date for the review of its NDA for risdiplam by three months to Aug. 24 due to a recent submission of additional data made by Roche, including data from the pivotal SUNFISH Part 2 study.Sage Announces Restructuring, Including Workforce Reduction, to Conserve Cash SAGE Therapeutics Inc (NASDAQ: SAGE) announced a restructuring initiative that would help it to advance its corporate strategy and pipeline. The initiative includes elimination of about 53% of its workforce and a reduction in external expenses, which together is expected to result in annualized savings of about $170 million, of which $150 million is related to SG&A expenses.The company said the workforce reduction will primarily affect Zulresso CIV injection commercial operation and related SG&A support functions.Based on the current operating plan and assumptions, Sage expects its cash position to support operations into 2022.The stock added 1.07% to $29.34 in after-hours trading.Idera Announces Private Placement of Up to $20.7M Worth Common Stock and Warrants Idera Pharmaceuticals Inc (NASDAQ: IDRA) announced an funding agreement for privately placing shares of its common stock together with accompanying warrants to purchase additional shares of common stock in two tranches, with the second tranche to be made at the option of the investor.View more earnings on IBBDepending on the extent to which Tranche 2 is closed, and inclusive of proceeds from the exercise of warrants issuable in this private placement, the company said it will receive up to $20.7 million in gross proceeds.The company said it plans to use the proceeds primarily to fund completion of its ongoing ILLUMINATE-301 trial of its lead product tilsotolimod for the treatment of anti-PD-1 refractory metastatic melanoma.The stock surged up 29.03% to $1.60 in after-hours trading.Organovo Terminates Merger With Tarveda Organovo Holdings Inc (NASDAQ: ONVO), a developer of 3-D bioprinted tissues comprising human cells, said it has terminated the merger agreement with Tarveda Therapeutics, which was originally announced Dec. 16. The decision follows Organova's shareholders rejecting the merger at a special meeting of stockholders.The shareholders, meanwhile, approved the proposal to effect a reverse stock split of one share for every 20 to 40 shares of existing common stock.The stock slipped 3.30% to 28 cents in after-hours trading.MediciNova to Initiate Clinical Trial of Investigational Asset MN-166 For COVID-19-induced Respiratory Distress MediciNova, Inc. (NASDAQ: MNOV) said it will initiate a clinical trial of MN-166 for acute respiratory distress syndrome caused by COVID-19."We are very pleased to announce initiation of a clinical trial of MN-166 in ARDS caused by COVID-19. This study also will allow investigators to determine the optimal dose and route of administration in these very critical patients," said Yuichi Iwaki, CEO of MediciNova.Announcements On COVID-Related Impacts Myriad Genetics, Inc. (NASDAQ: MYGN) announced withdrawal of its 2020 financial guidance, citing the impact of the COVID-19 pandemic."....recent social distancing guidelines have had a significant impact on test volume trends in late March and into the fiscal fourth-quarter," said Bryan Riggsbee, interim president and CEO and chief financial officer at Myriad Genetics.Trillium Therapeutics Inc (NASDAQ: TRIL) said it expects a slowdown or potentially a pause in new patient enrolment in its TTI-621 and TTI-622 dose escalation studies. The company, however, said its strong financial position, with about $135 million in cash and investments, will enable it to tide through the crisis and also execute on its key strategic objectives.On The Radar IPO Keros Therapeutics, which develops therapies for hematological and neuromuscular disorders, said it has priced its upsized initial public offering, or IPO, of 6 million at $16 compared to the estimated range of $14-$16. The company's shares will begin trading on the Nasdaq under the ticker symbol KROS.See more from Benzinga * The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation * The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations * The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

By David Bautz, PhD, CFA NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Clinical Trial to Initiate for MN-166 in Patients with COVID-19 ARDS On April 8, 2020, MediciNova, Inc. (NASDAQ:MNOV) announced that a clinical trial of MN-166 (ibudilast) will be initiated in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (coronavirus disease 2019). The trial will

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Financial Update On February 13, 2020, MediciNova (NASDAQ:MNOV) filed Form 10-K with financial results for the full year 2019. As expected, the company did not report any revenues. Net loss for 2019 was $12.9 million, or $0.30 per share, compared to a net loss of $14.7 million, or $0.36 per share, in 2018. The $12.9 million net

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a clinical trial of MN-166 (ibudilast) for acute respiratory distress syndrome (ARDS) caused by COVID-19 (Coronavirus Disease 2019). The study will be conducted by Yale’s Advanced Therapies Group, which is co-directed by Richard Bucala, M.D., Ph.D., Chief, Rheumatology, Allergy & Immunology at Yale School of Medicine and Rheumatologist-in-Chief at Yale New Haven Health.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of idiopathic pulmonary fibrosis (IPF).

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, ...

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of glioblastoma. This new patent has improved therapeutic claims compared to the first patent which covers MN-166 (ibudilast) for the treatment of glioblastoma, which was granted last year, and has a later expiration date than the first patent. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than February 2039.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of amyotrophic lateral sclerosis (ALS). The allowed claims cover the use of MN-166 (ibudilast) to treat a patient diagnosed with ALS.  The allowed claims cover oral administration in a wide range of daily dosages.  Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2028.

Is MediciNova, Inc. (NASDAQ:MNOV) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting […]

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update MN-166 to be Developed for Severe Pneumonia and ARDS On March 9, 2020, MediciNova, Inc. (NASDAQ:MNOV) announced that based upon preclinical results that were recently published the company will develop MN-166 (ibudilast) as a treatment for severe pneumonia and acute respiratory distress syndrome (ARDS). ARDS

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...